Mifepristone improved insulin sensitivity and adiponectin levels in mice fed a HFD (Hashimoto et al., 2013), and mifepristone is reported to have anti-diabetes and anti-obesity effects in humans and mice (Gross et al., 2010; Bernal-Sore et al., 2018; Diaz-Castro et al., 2020; Gubbi et al., 2021). Here, INS is linked to obesity due to melanocortin 4 receptor deficiency.